JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...
Radiation is energy that moves from one place to another in a form that can be described as waves or particles. We are exposed to radiation in our everyday life. Some of the most familiar sources of ...
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...
Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...
- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and ...
Hosted on MSN
Alpha Tau expands Alpha DaRT into recurrent prostate cancer: What investors should watch
Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is launching a new safety study titled “A Safety Study of ...
- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT ®, the innovative alpha-radiation cancer therapy designed for potent and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results